前列地尔联合恩替卡韦治疗乙型肝炎肝衰竭合并腹水患者的临床效果

Clinical Effect of Alprostadil Combined with Entecavir in the Treatment of Hepatitis B Patients with Liver Failure and Ascites

目的:探讨前列地尔联合恩替卡韦治疗乙型肝炎肝衰竭合并腹水患者的临床效果。方法:研究102例乙型肝炎肝衰竭合并腹水患者的临床资料,将其分为对照组(51例)和观察组(51例),对照组给予恩替卡韦,观察组在此基础上给予前列地尔,比较两组患者各项肝功能指标,即谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)及治疗效果。结果:观察组患者各项肝功能指标变化显著优于对照组,对比具有统计学意义(P<0.05);观察组患者治疗总有效率(92.16%)明显高于对照组(80.39%),对比具有统计学意义(P<0.05)。结论:前列地尔联合恩替卡韦治疗乙型肝炎肝衰竭合并腹水患者的临床效果显著。

Objective： To explore the clinical effect of alprostadil combined with entecavir in the treatment of hepatitis B patients with liver failure and ascites. Methods： the clinical data of 102 cases of liver failure complicated with ascites of hepatitis B patients, divided into control group （51 cases） and observation group （51 cases）, the control group was given entecavir, on the basis of the observation group received alprostadil, compared two groups of patients with liver function indexes, namely alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, total bilirubin （TBIL） and the therapeutic effect. Results： the changes of liver function indexes in the observation group were significantly better than those in the control group, with a statistically significant difference （P〈O.05）. The total effective rate in the observation group （92.16%） was significantly higher than that in the control group （80.39%）, and the difference was statistically significant （P〈0.05）. Conclusion： the clinical effect of alprostadil combined with entecavir in the treatment of hepatitis B patients with liver failure combined with ascites is significant.